Hand-Foot Syndrome with Scleroderma-like Change Induced by the Oral Capecitabine: A Case Report.
10.3904/kjim.2007.22.2.109
- Author:
Sehe Dong LEE
1
;
Hye Jeong KIM
;
Seung Jae HWANG
;
Yoon Jung KIM
;
Seung Hyun NAM
;
Bong Seog KIM
Author Information
1. Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea. seog@e-bohun.or.kr
- Publication Type:Case Report
- Keywords:
Hand-foot syndrome;
Capecitabine;
Scleroderma
- MeSH:
Administration, Oral;
Aged;
Antimetabolites, Antineoplastic/administration & dosage/*adverse effects;
Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives;
Fluorouracil/administration & dosage/adverse effects/*analogs & derivatives;
Foot Dermatoses/*chemically induced/diagnosis;
Hand Dermatoses/*chemically induced/diagnosis;
Humans;
Male;
Risk Factors;
Scleroderma, Localized/*chemically induced/diagnosis
- From:The Korean Journal of Internal Medicine
2007;22(2):109-112
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hand-foot syndrome (HFS) is a well-known adverse event associated with capecitabine, a prodrug of 5-Fluorouracil (5-FU). HFS manifests as acral erythema, with swelling and dysesthesia of the palms and plantar aspects of the feet, which in the absence of dosage reduction or drug cessation, progresses to moist desquamation and ulceration, resulting in serious infections and loss of function. We report a case of HFS, with scleroderma-like changes, apparently induced by capecitabine. In our case, capecitabine, given in the recommended dosage was observed to lead to hyperpigmentation of the palms and soles, followed by a distinct keratoderma-like thickening unfamiliar to usual cases of HFS. This case may provide important clues for revising the definition of HFS, and allow the formation of effective preventive strategies for this side effect of chemotherapy.
